Transcriptomics

Dataset Information

0

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma


ABSTRACT: To investigate the effects of the I/IIb HDAC inhibitor, Purinostat Mesylate (PM, also called HL13) on gene expression in multiple myeloma. The MM.1S cells were treated with Ctrl (DMSO) or HL13 (5nM) for 24 hours. Then the cells were collected and total RNA were isolation by Trizol. The expression profiling by array generated following the recommended protocol of Affymetrix GeneChip Human Transcriptome Array 2.0. To investigate the effects of the I/IIb HDAC inhibitor, Purinostat Mesylate (PM, also called HL13) on gene expression in multiple myeloma. The MM.1S cells were treated with Ctrl (DMSO) or HL13 (5nM) for 24 hours. Then the cells were collected and total RNA were isolation by Trizol. The expression profiling by array generated following the recommended protocol of Affymetrix GeneChip Human Transcriptome Array 2.0.

ORGANISM(S): Homo sapiens

PROVIDER: GSE296480 | GEO | 2025/07/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2025-05-23 | GSE297562 | GEO
2025-05-15 | GSE296835 | GEO
2025-05-15 | GSE296833 | GEO
2013-07-26 | E-GEOD-49224 | biostudies-arrayexpress
2024-01-31 | GSE253488 | GEO
2023-11-11 | GSE189273 | GEO
2011-01-28 | E-GEOD-26903 | biostudies-arrayexpress
| PRJNA1261787 | ENA
| PRJNA1259464 | ENA
| PRJNA1261791 | ENA